Tim A Kanters

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. doi request reprint A conceptual disease model for adult Pompe disease
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Box 1738, 3000DR, Rotterdam, The Netherlands
    Orphanet J Rare Dis 10:112. 2015
  2. doi request reprint Comparison of EQ-5D and SF-6D utilities in Pompe disease
    T A Kanters
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P O Box 1738, 3000, Dr, Rotterdam, The Netherlands
    Qual Life Res 24:837-44. 2015
  3. pmc Orphan drugs expenditure in the Netherlands in the period 2006-2012
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3000DR, The Netherlands
    Orphanet J Rare Dis 9:154. 2014
  4. pmc Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
    Tim A Kanters
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P, O, Box 1738, 3000DR Rotterdam, The Netherlands
    Orphanet J Rare Dis 9:75. 2014
  5. doi request reprint The impact of informal care for patients with Pompe disease: an application of the CarerQol instrument
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P O Box 1738, 3000 DR Rotterdam, The Netherlands Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands Electronic address
    Mol Genet Metab 110:281-6. 2013
  6. pmc Systematic review of available evidence on 11 high-priced inpatient orphan drugs
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, PO Box 1738, 3000DR Rotterdam, The Netherlands
    Orphanet J Rare Dis 8:124. 2013
  7. doi request reprint A new prevention paradox: the trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers
    Tim A Kanters
    Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Soc Sci Med 76:150-8. 2013
  8. pmc Burden of illness of Pompe disease in patients only receiving supportive care
    Tim A Kanters
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Inherit Metab Dis 34:1045-52. 2011
  9. doi request reprint Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Tim A Kanters
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000DR Rotterdam, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 15:557-9. 2015

Detail Information

Publications9

  1. doi request reprint A conceptual disease model for adult Pompe disease
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Box 1738, 3000DR, Rotterdam, The Netherlands
    Orphanet J Rare Dis 10:112. 2015
    ....
  2. doi request reprint Comparison of EQ-5D and SF-6D utilities in Pompe disease
    T A Kanters
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P O Box 1738, 3000, Dr, Rotterdam, The Netherlands
    Qual Life Res 24:837-44. 2015
    ..We compared the psychometric properties of EQ-5D and SF-6D in patients with this disease and assessed their convergent validity, discriminative ability and sensitivity to change...
  3. pmc Orphan drugs expenditure in the Netherlands in the period 2006-2012
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3000DR, The Netherlands
    Orphanet J Rare Dis 9:154. 2014
    ..However, overall, the budget impact of orphan drugs can still be substantial. In this study, we assess the uptake and budget impact of orphan drugs in the Netherlands...
  4. pmc Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
    Tim A Kanters
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P, O, Box 1738, 3000DR Rotterdam, The Netherlands
    Orphanet J Rare Dis 9:75. 2014
    ..However, the costs of therapy are very high. In this paper, we assess the cost-effectiveness of enzyme replacement therapy in infantile Pompe disease...
  5. doi request reprint The impact of informal care for patients with Pompe disease: an application of the CarerQol instrument
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, P O Box 1738, 3000 DR Rotterdam, The Netherlands Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands Electronic address
    Mol Genet Metab 110:281-6. 2013
    ..Patients with Pompe disease, a rare progressive neuromuscular disorder, receive a considerable amount of informal care. In this study, we examined the impact of providing informal care to patients with Pompe disease...
  6. pmc Systematic review of available evidence on 11 high-priced inpatient orphan drugs
    Tim A Kanters
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, PO Box 1738, 3000DR Rotterdam, The Netherlands
    Orphanet J Rare Dis 8:124. 2013
    ..This study systematically reviews the available evidence on clinical effectiveness, cost-effectiveness and budget impact for orphan drugs...
  7. doi request reprint A new prevention paradox: the trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers
    Tim A Kanters
    Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Soc Sci Med 76:150-8. 2013
    ..This highlights a new prevention paradox: improving the level playing field for health insurers will inevitably limit their incentives for promoting the health of their clients...
  8. pmc Burden of illness of Pompe disease in patients only receiving supportive care
    Tim A Kanters
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Inherit Metab Dis 34:1045-52. 2011
    ....
  9. doi request reprint Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Tim A Kanters
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000DR Rotterdam, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 15:557-9. 2015
    ....